Kidney cancer is characterized by aberrant methylation of tissue-specific enhancers that are prognostic for overall survival

Clinical Cancer Research

Volumn 20, Issue 16, 2014, Pages 4349-4360

  Hu, Caroline Y ^a   Mohtat, Davoud ^a   Yu, Yiting ^a   Ko, Yi An ^b   Shenoy, Niraj ^a   Bhattacharya, Sanchari ^a   Izquierdo, Maria C ^b   Park, Ae Seo Deok ^b   Giricz, Orsolya ^a   Vallumsetla, Nishanth ^a   Gundabolu, Krishna ^a   Ware, Kristin ^c   Bhagat, Tushar D ^a   Suzuki, Masako ^a   Pullman, James ^c   Liu, X Shirley ^d   Greally, John M ^a   Susztak, Katalin ^b   Verma, Amit ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1BETA; PROTEIN AHR; PROTEIN AP2A; PROTEIN HAIRY; SMAD6 PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; MESSENGER RNA; TUMOR MARKER;

ARTICLE; BINDING SITE; CANCER PROGNOSIS; CHEMOSENSITIVITY; COHORT ANALYSIS; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA METHYLATION; ENHANCER REGION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; KIDNEY CANCER; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN MOTIF; SIGNAL TRANSDUCTION; ANTIBODY SPECIFICITY; CASE CONTROL STUDY; CELL CULTURE; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; KIDNEY CARCINOMA; KIDNEY TUMOR; MORTALITY; PROGNOSIS; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; CELLS, CULTURED; COHORT STUDIES; DNA METHYLATION; ENHANCER ELEMENTS, GENETIC; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; ORGAN SPECIFICITY; PROGNOSIS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE;

EID: 84905992252     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0494     Document Type: Article

References (42)

1. Alvarez H, Opalinska J, Zhou L, Sohal D, Fazzari MJ, Yu Y, et al. Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. PLoS Genet 2011;7:e1001356.
2. De S, Shaknovich R, Riester M, Elemento O, Geng H, Kormaksson M, et al. Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. PLoS Genet 2013;9:e1003137.
3. Suzuki M, Oda M, Ramos MP, Pascual M, Lau K, Stasiek E, et al. Late-replicating heterochromatin is characterized by decreased cytosine methylation in the human genome. Genome Res 2011;21:1833-40.
4. Steidl U, Steidl C, Ebralidze A, Chapuy B, Han HJ, Will B, et al. A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. J Clin Invest 2007;117:2611-20. (Pubitemid 47494362)
5. Lamprecht B, Walter K, Kreher S, Kumar R, Hummel M, Lenze D, et al. Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat Med 2010;16:571-9.
6. Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013;153:320-34.
7. Baldewijns MM, van Vlodrop IJ, Schouten LJ, Soetekouw PM, de Bruine AP, van Engeland M. Genetics and epigenetics of renal cell cancer. Biochim Biophys Acta 2008;1785:133-55.
8. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353:2477-90. (Pubitemid 41770167)
9. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008;14:435-46.
10. Powles T, Chowdhury S, Jones R, Mantle M, Nathan P, Bex A, et al. Sunitinib and other targeted therapies for renal cell carcinoma. Br J Cancer 2011;104:741-5.
11. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011;469:539-42.
12. Murtaugh LC, Stanger BZ, Kwan KM, Melton DA. Notch signaling controls multiple steps of pancreatic differentiation. Proc Natl Acad Sci U S A 2003;100:14920-5. (Pubitemid 37517992)
13. Esteller M. Cancer epigenetics:DNAmethylation and chromatin alterations in human cancer. Adv Exp Med Biol 2003;532:39-49. (Pubitemid 37176778)
14. Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010;17:13-27.
15. Khulan B, Thompson RF, Ye K, Fazzari MJ, Suzuki M, Stasiek E, et al. Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res 2006;16:1046-55. (Pubitemid 44162264)
16. Thompson RF, Reimers M, Khulan B, Gissot M, Richmond TA, Chen Q, et al. An analytical pipeline for genomic representations used for cytosine methylation studies. Bioinformatics 2008;24:1161-7. (Pubitemid 351594165)
17. Arai E, Kanai Y. Genetic and epigenetic alterations during renal carcinogenesis. Int J Clin Exp Pathol 2010;4:58-73.
18. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009;41:178-86.
19. Ball MP, Li JB, Gao Y, Lee JH, LeProust EM, Park IH, et al. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol 2009;27:361-8.
20. Creighton CJ, Morgan M, Gunaratne PH, Wheeler DA, Gibbs RA, Robertson A, et al. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499:43-9.
21. Woroniecka KI, Park AS, Mohtat D, Thomas DB, Pullman JM, Susztak K. Transcriptome analysis of human diabetic kidney disease. Diabetes 2011;60:2354-69.
22. Oda M, Glass JL, Thompson RF, Mo Y, Olivier EN, Figueroa ME, et al. High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers. Nucleic Acids Res 2009;37:3829-39.
23. Anguiano A, Tuchman SA, Acharya C, Salter K, Gasparetto C, Zhan F, et al. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. J Clin Oncol 2009;27:4197-203.
24. Figueroa ME, Reimers M, Thompson RF, Ye K, Li Y, Selzer RR, et al. An integrative genomic and epigenomic approach for the study of transcriptional regulation. PLoS ONE 2008;3:e1882.
25. Figueroa ME, Wouters BJ, Skrabanek L, Glass J, Li Y, Erpelinck- Verschueren CA, et al. Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. Blood 2009;113:2795-804.
26. Shin H, Liu T, Manrai AK, Liu XS. CEAS: cis-regulatory element annotation system. Bioinformatics 2009;25:2605-6.
27. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000;25:25-9. (Pubitemid 30257031)
28. Ernst J, Kheradpour P, Mikkelsen TS, Shoresh N, Ward LD, Epstein CB, et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 2011;473:43-9.
29. Ernst J, Kellis M. ChromHMM: automating chromatin-state discovery and characterization. Nat Methods 2012;9:215-6.
30. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28. (Pubitemid 34587077)
31. Aiden AP, Rivera MN, Rheinbay E, Ku M, Coffman EJ, Truong TT, et al. Wilms tumor chromatin profiles highlight stem cell properties and a renal developmental network. Cell Stem Cell 2010;6:591-602.
32. Cowey CL, Rathmell WK. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep 2009;11:94-101.
33. Morris MR, Ricketts CJ, Gentle D, McRonald F, Carli N, Khalili H, et al. Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour-suppressor genes in renal cell carcinoma. Oncogene 2011;30:1390-401.
34. Morris MR, Ricketts C, Gentle D, Abdulrahman M, Clarke N, Brown M, et al. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene 2010;29:2104-17.
35. Mosashvilli D, Kahl P, Mertens C, Holzapfel S, Rogenhofer S, Hauser S, et al. Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma. Cancer Sci 2010;101:2664-9.
36. Minardi D, Lucarini G, Filosa A, Milanese G, Zizzi A, Di Primio R, et al. Prognostic role of global DNA-methylation and histone acetylation in pT1a clear cell renal carcinoma in partial nephrectomy specimens. J Cell Mol Med 2009;13:2115-21.
37. Kanao K, Mikami S, Mizuno R, Shinojima T, Murai M, Oya M. Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors. J Urol 2008;180:1131-6.
38. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 2003;9:4641-52. (Pubitemid 37323266)
39. Casalena G, Daehn I, Bottinger E. Transforming growth factor-beta, bioenergetics, and mitochondria in renal disease. Semin Nephrol 2012;32:295-303.
40. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-32.
41. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002;21:5400-13. (Pubitemid 34983477)
42. Negrotto S, Hu Z, Alcazar O, Ng KP, Triozzi P, Lindner D, et al. Noncytotoxic differentiation treatment of renal cell cancer. Cancer Res 2011;71:1431-41.